The conversation is about the significant hair regrowth a person experienced after three years of using finasteride. People are expressing surprise and congratulations on the noticeable improvement.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
A 23-year-old male with early stage 4 hair loss is using a treatment routine that includes minoxidil 5% with tretinoin once daily, finasteride 1mg every other day, 2.5mg oral minoxidil every other day, and derma rolling twice a week. The discussion is about whether using minoxidil twice a day is better than combining it with tretinoin once a day.
The user experienced positive hair regrowth using topical minoxidil, along with other factors like shorter hair, castor oil, and hair masks. The user is optimistic about further progress and wants to avoid baldness.
The user is using 5% minoxidil foam twice daily and 1mg finasteride nightly for hair loss, and has seen positive results in 3 months. They plan to continue the treatment indefinitely as it provides reassurance against hair loss.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The user reports significant hair regrowth after 90 days using oral finasteride, minoxidil, and biotin. Another user comments on the impressive progress and predicts even thicker hair in a year.
The user is experiencing hair loss despite using finasteride three times a week due to side effects and is considering alternatives like topical finasteride, estrogen blockers, or dutasteride. They are also interested in potential treatments like GT20029 and pyrilutamide.
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
A 35-year-old man shared his hair transplant experience in Tijuana, Mexico, choosing Artline for 5,000 grafts at a lower cost than U.S. clinics. He plans to use topical minoxidil and possibly microneedling for better results.
A 52-year-old man experienced positive hair regrowth after three months on a daily regimen of 1mg finasteride and 3mg minoxidil. Users discussed dosage recommendations and shared advice on finasteride use, with some expressing amazement at the results.
The conversation discusses hair regrowth using finasteride, minoxidil, biotin, and vitamin D over three months, with visible results. One person asks about the daily dosage of vitamin D and biotin.
An 18-year-old is using minoxidil, finasteride, and tretinoin for hair loss, with concerns about uneven temple progress. They have been on minoxidil for 3.5 months and finasteride for 2 months.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
A user experienced hair regrowth after 3 months using finasteride, both topical and oral minoxidil, 0.5mm microneedling daily, and 300mg testosterone. They reported noticeable muscle gains and no side effects while being on testosterone replacement therapy.
The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
The user has been using a combination of finasteride and minoxidil for three months and is seeing progress in hair regrowth. Other users encourage them to continue the treatment for further improvement.
The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.
The user reports positive results in hair growth using daily oral finasteride (1.2mg), minoxidil (3mg), and biotin (2.5mg), along with collagen peptides, exercise, and weightlifting. Other users comment on the progress and discuss the effectiveness and side effects of these treatments.
A user underwent a hair transplant with 3500 grafts after trying treatments like finasteride and minoxidil, preferring a local clinic in Toronto over traveling to Turkey. The user plans to continue using finasteride to maintain existing hair, as the transplanted hair is DHT resistant.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Triple Hair's TH-16, a product claimed to be more effective than Minoxidil 5%, has been released; it contains melatonin and resveratrol. One user reported success with topical melatonin and dermarolling.
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.